Amplyx
2006
FOUNDED
PRIVATE
STATUS
11-20
EMPLOYEES
Series C
LATEST DEAL TYPE
$118M
LATEST DEAL AMOUNT
21
INVESTORS
Description
Developer of broad-spectrum antifungal agents designed to treat invasive fungal infections. The company's small-molecule therapy, APX001, uses both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenient treatment after discharge from hospital, enabling patients undergoing chemotherapy and other immunosuppressive treatments, with compromised immune systems, to get proper treatment for life-threatening invasive fungal infections due to candida, aspergillus and rare molds.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Primary Office
- 12730 High Bluff Drive
- Suite 160
- San Diego, CA 92130
- United States
+1 (858) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Amplyx’s full profile, request a free trial.
Amplyx Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series C) | 09-Jan-2020 | $118M | 00000 | Completed | Generating Revenue | |
| 8. Accelerator/Incubator | 28-Feb-2017 | 000.00 | Completed | Generating Revenue | ||
| 7. Later Stage VC (Series B) | 09-Feb-2016 | 000.00 | 000.00 | 0000 | Completed | Generating Revenue |
| 6. Grant | 00.000 | 00.000 | Completed | Generating Revenue | ||
| 5. Grant | 01-Jul-2014 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 4. Grant | 01-Jul-2013 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 3. Grant | 01-Aug-2012 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 2. Grant | 01-Jul-2011 | $700K | $2.23M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 01-Jan-2011 | $2.23M | $2.23M | 000 | Completed | Startup |
Amplyx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 000,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B | 000,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
| Series A | 8,243,027 | $0.001000 | 8% | $0.27 | $0.27 | 1x | $0.27 | 2.31% |
Amplyx Competitors (32)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Samumed | Private Equity-Backed | San Diego, CA | 000 | 00000 | 0000000 0000 | 00000 |
| 000 | Venture Capital-Backed | Manchester, United Kingdom | 00 | 000.00 | 000000 - 000 | 000.00 |
| 000000 00000 | Private Equity-Backed | Durham, NC | 00 | 00000 | 000000000000 | 00000 |
| 00000 000000 | Venture Capital-Backed | New York, NY | 0000 | 0000000000 0 | 0000 | |
| 000000 00000000000 | Private Equity-Backed | Copenhagen, Denmark | 0000 | 000000000000 |
Amplyx Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Arix Bioscience | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Generation Ventures (Palo Alto) | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Lundbeckfonden | Limited Partner | Minority | 000 0000 | 000000 0 | ||
| Lundbeckfond Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Lymo Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
Amplyx Executive Team (12)
4 Former Executives
You’re viewing 5 of 12 executives. Get the full list »Amplyx Board Members (13)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Anand Mehra MD | Sofinnova Investments | Board Member | 000 0000 | |
| Edward Mathers | Self | Board Member | 000 0000 | |
| Elaine Heron Ph.D | Amplyx | Board Member | 000 0000 | |
| Johan Kördel Ph.D | Lundbeckfonden | Board Member | 000 0000 | |
| Mark Chin | Arix Bioscience | Board Observer | 000 0000 |
5 Former Board Members
You’re viewing 5 of 13 board members. Get the full list »